Retatrutide Prescribed Online to Michigan Residents

Medical Weight Loss Treatment in Michigan

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Michigan

Michigan spans two peninsulas, thousands of miles of Great Lakes shoreline, and communities as diverse as downtown Detroit and the remote Upper Peninsula. OmniRx Health serves all of it. Whether you're in the automotive heart of Metro Detroit, the craft beer culture of Grand Rapids, the cherry orchards of Traverse City, or the wilderness of the UP, our telehealth platform brings expert care to you. No more planning around the Mackinac Bridge or seasonal road closures.

OmniRx Health providers are licensed by the Michigan Board of Medicine for comprehensive telehealth services across both peninsulas.

Michigan pharmacies in Detroit, Grand Rapids, Traverse City, and throughout the UP ensure prescription access with statewide delivery.

Michigan's telehealth laws support virtual care delivery with provisions for both synchronous and asynchronous services.

Michigan requires commercial insurers to cover telehealth, and the state has expanded Medicaid telehealth coverage for eligible residents.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Michigan?: Yes, telehealth is legal and well-supported in Michigan. State law allows licensed providers to deliver comprehensive virtual care including prescriptions across both peninsulas.
Can Upper Peninsula residents use telehealth?: Absolutely. Telehealth is ideal for UP residents who may be hours from specialist care. Our platform connects you with board-certified providers regardless of your distance from medical centers.
Does Michigan Medicaid cover telehealth?: Yes, Michigan Medicaid covers telehealth services for eligible members. The state has expanded virtual care coverage to improve access across all regions.